• Self healing substances?
• Greek: autos—self, akos—healing substance
or remedy.
• Autocoids.
Autocoids
• Self healing substances.
• Also called as local hormones.
• Mostly released in response to injury &
immunological insult.
• Amine autacoids: Histamine, 5-HT (Serotonin).
• Lipid derived autacoids: PGs, LTs, PAF.
• Peptide autacoids: Plasma kinins (Bradykinin),
Angiotensin etc.
• Others: Cytokines (ILs, TNFα, GM-CSF, etc.) &
several peptides viz gastrin, somatostatin, VIP etc.
HISTAMINE & ANTIHISTAMINICS
Dr. M Kanhaiah
Dept of Pharmacology
Histamine
(Tissue amine)
 High levels in skin, bronchial & intestinal
mucosa, CSF, bone marrow etc
 Released from mast cells & basophils
(Type I hypersensitivity...LTs, PAF>>>Hist)
 GPCRs
• Decarboxylation of L-histidine
• Mast cells (predominant sites of storage)
• Stimuli for its release (IgE mediated release,
chemical & mechanical)
Histamine releasers
 Tissue damage (trauma, sting, venoms)
 Polymers (Dextran, PVP)
 Some basic drugs;
 d-tubocurarine, morphine, vancomycin, SCh, hydralazine etc
 Vancomycin-induced red-man syndrome, involving hypotension & flushing
of upper body & face
 Heat, cold, sunlight, x-ray
 Ag-Ab reaction involving IgE antibodies
Histamine Release Inhibitors
• β2 agonists
• Methylxanthines
• Mast cell stabilizers (cromoglycate, ketotifen)
H1 Gq coupled (IP3, DAG, Ca2+)
H2 Gs coupled (cAMP)
H3 Gi coupled
H4 Gi
Receptors
H1 activation
 Capillary dilation (via NO & PGI2) - fall in BP
 Capillary permeability – edema
 Bronchial smooth muscle contraction (Gq)
 Activation of peripheral nociceptive receptors via
Substance-P (pain & pruritus)
 Decreased AV nodal conduction (Gi)
• Exocrine secretions
• Adrenal medulla (secondary rise in BP)
• Maintenance of wakefulness
– H1 antagonists cause sedative action by blocking this
function in hypothalamus & midbrain
• Betahistine:
• It is an orally active, somewhat H1 selective
histamine analogue.
• Used to control vertigo in pts of Meniéré’s disease:
(by causing vasodilatation in the internal ear).
• It is contraindicated in asthmatics & ulcer patients.
H2 activation
 Gastric acid secretion increased – ulcers
 Increased SA & AV-nodal rate
 Positive chronotropic & inotropic
• H4 receptors primarily are found in cells of hematopoietic origin (eosinophils,
dendritic cells, mast cells, monocytes, basophils, & T cells)
• Activation of H4 receptors is associated with induction of cellular shape change,
chemotaxis, secretion of cytokines and upregulation of adhesion molecules
• H4 antagonists may be useful inhibitors of allergic and inflammatory responses
H1 antagonists
Drug M block Sedation Antimotion Other characteristics
Diphenhydramine +++ +++ +++ Widely used OTC
Promethazine +++ +++ ++ Some α block & LA
action
Chlorpheniramine ++ ++ ++ Possible CNS
stimulation
Meclizine ++ ++ ++++ Highly effective in
motion sickness
Hydroxyzine ++ +++ ++ Used as sedative
Loratadine +/- 0 0 No CNS entry
Fexofenadine +/- 0 0 No CNS entry
Anticholinergic action
SECOND GENERATION ANTIHISTAMINICS (SGA) or NEWER ANTIHISTAMINICS
 Higher H1 selectivity
 Devoid of anticholinergic side effects
 Absence of CNS depression
 Some have additional antiallergic
properties (act on LTs & PAF)
Advantages:
 Do not impair psychomotor function (driving etc).
 No sleepiness.
 Do not potentiate CNS depressants.
 Additional anti-allergic properties.
Fexofenadine:
 Active metabolite of Terfenadine.
 Terfenadine & Astemizole are withdrawn now due to TdP.
 Doesn’t prolong QTc interval (less propensity for Torsades de Pointes)
 No interaction with CYP3A4 inhibitors.
 Not entirely safe in pts with long QT, Bradycardia / hypokalemia.
 Doesn’t cross BBB.
 Free of atropinic (anti-cholinergic) side effects.
Loratidine:
 Long & fast-acting selective H1 antagonist
 Devoid of CNS depression
 No cardiac arrhythmias in overdose
 Seizures have been reported
Cetirizine:
 Metabolite of Hydroxyzine
 Poor CNS entry
 Subjective somnelence at higher doses
 No interaction with CYP3A4 inhibitors
 Additional antiallergic actions (inhibits histamine release from platelets &
eosinophil chemotaxis)
 High & longer concentrations in skin (superior efficacy in urticaria / atopic
dermatitis)
 OD dose despite elimination t½ of 10 hrs.
Levocetirizine:
 Active R(-) enantiomer of Cetirizine
 Effective at half dose
 Few side effects
Azelastine:
 Newer drug with good topical activity
 Additional antiallergic properties (inhibits histamine release & reaction due to LTs,
PAF)
 Bronchodilating property
 Active metabolite (longer-acting)
 Metabolism inhibited by CYP3A4 inhibitors
 Nasal spray in rhinitis provides quick relief lasting 12 hrs
 Weight gain observed after oral use
Other SGAs:
 Mizolastine
 Ebastine
 Desloratadine
 Rupatidine
Uses:
Allergic disorders:
 Do not suppress AG:AB reaction but blocks histamine’s actions.
 Effectively control itching, urticaria, allergic conjunctivitis etc.
 Efficacy is secondary to Adrenaline (life saving drug) in
laryngeal edema & anaphylaxis.
 Ineffective in Bronchial Asthma (LTs & PAF play role).
 Type I hypersensitivity to drugs is suppressed (NOT anaphylaxis &
 Motion sickness (Promethazine, Diphenhydramine, Cyclizine)
 Nausea & vomiting of pregnancy/radiation sickness (Promethazine)
 Preoperative sedation (Promethazine, Hydroxyzine)
 OTC for cold (Sx relief by anticholinergic-sedative actions)
 Parkinson’s disease (Orphenadrine, Promethazine)
 Acute EPS caused by antipsychotics/D2 blockers (Promethazine)
 Pruritus (older preparations are much effective)
 Vertigo (Cinnarizine)
 Cough (Sx relief by sedative-anticholinergic action e.g.
Chlorpheniramine, Diphenhydramine, Promethazine)
ADRs:
 Sedation
 Synergism with other CNS depressants (Alcohol, Barbiturates,
Opiates, BZDs etc)
 Anti muscarinic side effects (dry mouth, blurred vision)
 Arrhythmias (H1 & M2 receptor-mediated)
 Careful while using in pts with BPH & Glaucoma
H2 Blockers
• Primarily used in peptic ulcer, GERD & other
gastric hypersecretory states

Histamine & antihistaminics

  • 1.
    • Self healingsubstances?
  • 2.
    • Greek: autos—self,akos—healing substance or remedy. • Autocoids.
  • 3.
    Autocoids • Self healingsubstances. • Also called as local hormones. • Mostly released in response to injury & immunological insult.
  • 4.
    • Amine autacoids:Histamine, 5-HT (Serotonin). • Lipid derived autacoids: PGs, LTs, PAF. • Peptide autacoids: Plasma kinins (Bradykinin), Angiotensin etc. • Others: Cytokines (ILs, TNFα, GM-CSF, etc.) & several peptides viz gastrin, somatostatin, VIP etc.
  • 5.
    HISTAMINE & ANTIHISTAMINICS Dr.M Kanhaiah Dept of Pharmacology
  • 6.
    Histamine (Tissue amine)  Highlevels in skin, bronchial & intestinal mucosa, CSF, bone marrow etc  Released from mast cells & basophils (Type I hypersensitivity...LTs, PAF>>>Hist)  GPCRs
  • 10.
    • Decarboxylation ofL-histidine • Mast cells (predominant sites of storage) • Stimuli for its release (IgE mediated release, chemical & mechanical)
  • 11.
    Histamine releasers  Tissuedamage (trauma, sting, venoms)  Polymers (Dextran, PVP)  Some basic drugs;  d-tubocurarine, morphine, vancomycin, SCh, hydralazine etc  Vancomycin-induced red-man syndrome, involving hypotension & flushing of upper body & face  Heat, cold, sunlight, x-ray  Ag-Ab reaction involving IgE antibodies
  • 12.
    Histamine Release Inhibitors •β2 agonists • Methylxanthines • Mast cell stabilizers (cromoglycate, ketotifen)
  • 13.
    H1 Gq coupled(IP3, DAG, Ca2+) H2 Gs coupled (cAMP) H3 Gi coupled H4 Gi Receptors
  • 14.
    H1 activation  Capillarydilation (via NO & PGI2) - fall in BP  Capillary permeability – edema  Bronchial smooth muscle contraction (Gq)  Activation of peripheral nociceptive receptors via Substance-P (pain & pruritus)  Decreased AV nodal conduction (Gi)
  • 16.
    • Exocrine secretions •Adrenal medulla (secondary rise in BP) • Maintenance of wakefulness – H1 antagonists cause sedative action by blocking this function in hypothalamus & midbrain
  • 18.
    • Betahistine: • Itis an orally active, somewhat H1 selective histamine analogue. • Used to control vertigo in pts of Meniéré’s disease: (by causing vasodilatation in the internal ear). • It is contraindicated in asthmatics & ulcer patients.
  • 19.
    H2 activation  Gastricacid secretion increased – ulcers  Increased SA & AV-nodal rate  Positive chronotropic & inotropic
  • 21.
    • H4 receptorsprimarily are found in cells of hematopoietic origin (eosinophils, dendritic cells, mast cells, monocytes, basophils, & T cells) • Activation of H4 receptors is associated with induction of cellular shape change, chemotaxis, secretion of cytokines and upregulation of adhesion molecules • H4 antagonists may be useful inhibitors of allergic and inflammatory responses
  • 26.
    H1 antagonists Drug Mblock Sedation Antimotion Other characteristics Diphenhydramine +++ +++ +++ Widely used OTC Promethazine +++ +++ ++ Some α block & LA action Chlorpheniramine ++ ++ ++ Possible CNS stimulation Meclizine ++ ++ ++++ Highly effective in motion sickness Hydroxyzine ++ +++ ++ Used as sedative Loratadine +/- 0 0 No CNS entry Fexofenadine +/- 0 0 No CNS entry
  • 28.
  • 29.
    SECOND GENERATION ANTIHISTAMINICS(SGA) or NEWER ANTIHISTAMINICS  Higher H1 selectivity  Devoid of anticholinergic side effects  Absence of CNS depression  Some have additional antiallergic properties (act on LTs & PAF)
  • 30.
    Advantages:  Do notimpair psychomotor function (driving etc).  No sleepiness.  Do not potentiate CNS depressants.  Additional anti-allergic properties.
  • 31.
    Fexofenadine:  Active metaboliteof Terfenadine.  Terfenadine & Astemizole are withdrawn now due to TdP.  Doesn’t prolong QTc interval (less propensity for Torsades de Pointes)  No interaction with CYP3A4 inhibitors.  Not entirely safe in pts with long QT, Bradycardia / hypokalemia.  Doesn’t cross BBB.  Free of atropinic (anti-cholinergic) side effects.
  • 32.
    Loratidine:  Long &fast-acting selective H1 antagonist  Devoid of CNS depression  No cardiac arrhythmias in overdose  Seizures have been reported
  • 33.
    Cetirizine:  Metabolite ofHydroxyzine  Poor CNS entry  Subjective somnelence at higher doses  No interaction with CYP3A4 inhibitors  Additional antiallergic actions (inhibits histamine release from platelets & eosinophil chemotaxis)  High & longer concentrations in skin (superior efficacy in urticaria / atopic dermatitis)  OD dose despite elimination t½ of 10 hrs.
  • 34.
    Levocetirizine:  Active R(-)enantiomer of Cetirizine  Effective at half dose  Few side effects
  • 35.
    Azelastine:  Newer drugwith good topical activity  Additional antiallergic properties (inhibits histamine release & reaction due to LTs, PAF)  Bronchodilating property  Active metabolite (longer-acting)  Metabolism inhibited by CYP3A4 inhibitors  Nasal spray in rhinitis provides quick relief lasting 12 hrs  Weight gain observed after oral use
  • 36.
    Other SGAs:  Mizolastine Ebastine  Desloratadine  Rupatidine
  • 37.
    Uses: Allergic disorders:  Donot suppress AG:AB reaction but blocks histamine’s actions.  Effectively control itching, urticaria, allergic conjunctivitis etc.  Efficacy is secondary to Adrenaline (life saving drug) in laryngeal edema & anaphylaxis.  Ineffective in Bronchial Asthma (LTs & PAF play role).  Type I hypersensitivity to drugs is suppressed (NOT anaphylaxis &
  • 38.
     Motion sickness(Promethazine, Diphenhydramine, Cyclizine)  Nausea & vomiting of pregnancy/radiation sickness (Promethazine)  Preoperative sedation (Promethazine, Hydroxyzine)  OTC for cold (Sx relief by anticholinergic-sedative actions)  Parkinson’s disease (Orphenadrine, Promethazine)  Acute EPS caused by antipsychotics/D2 blockers (Promethazine)
  • 39.
     Pruritus (olderpreparations are much effective)  Vertigo (Cinnarizine)  Cough (Sx relief by sedative-anticholinergic action e.g. Chlorpheniramine, Diphenhydramine, Promethazine)
  • 40.
    ADRs:  Sedation  Synergismwith other CNS depressants (Alcohol, Barbiturates, Opiates, BZDs etc)  Anti muscarinic side effects (dry mouth, blurred vision)  Arrhythmias (H1 & M2 receptor-mediated)  Careful while using in pts with BPH & Glaucoma
  • 43.
    H2 Blockers • Primarilyused in peptic ulcer, GERD & other gastric hypersecretory states